Ohio is currently home to 3204 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Gabrail Cancer Center (GCC) Canton Facility, Canton, Ohio
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Register for Updates
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
NCT05681351
Recruiting
The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Severe Hypertriglyceridemia
Register for Updates
Study of CHS-114 in Participants With Advanced Solid Tumors
NCT05635643
Recruiting
This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
Register for Updates
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
NCT05602363
Recruiting
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Taylor Cancer Research Center, Maumee, Ohio
Conditions: B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
Register for Updates
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
NCT05118789
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
AlloSure Lung Assessment and Metagenomics Outcomes Study
NCT05050955
Recruiting
ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Ohio State University, Columbus, Ohio
Conditions: Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection
Register for Updates
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT04815876
Recruiting
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora. Preliminary data demonstrates that a transperineal MRI-targeted biopsy approach under local anesthesia compared to the standard practice transrectal MRI-targeted prostate biopsy has a much lower risk of infection, comparable pain/discomfort and may improve detection of prostate cancer. This randomiz... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Infection
Register for Updates
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541
Recruiting
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as: * Monotherapy, or * Combination therapy: * epcoritamab + venetoclax * epcoritamab + pirtobrutinib In Non-United States (US) Participants Only: Treatment-naïve (TN) high risk (HR) (CLL): • epcoritamab + pirtobrutinib Combination therapy for Ri... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-naïve High Risk Chronic Lymphocytic Leukemia, Richter's Syndrome
Register for Updates
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230
Recruiting
This is an open-label single arm study. All patients will receive the study drug. The aim of the study is to compare overall survival (OS) of patients with recurrent brain tumor, known as Glioblastoma (GBM) having high levels of a protein, Trophoblast cell surface antigen 2 (Trop-2), expression on treatment with Sacituzumab Govitecan (SG) versus lomustine only which has been used in the past.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio
Conditions: Recurrent Glioblastoma
Register for Updates
A Phase 1B/2 Study of RP1 in Solid Organ Transplant Patients With Advanced Cutaneous Malignancies
NCT04349436
Recruiting
This Phase 1B/2 study is a multicenter, open-label, study of RP1 to investigate the (a) objective response rate, in addition to (b) safety and tolerability of RP1 for the treatment of advanced cutaneous malignancies in up to 65 evaluable organ transplant recipients. This will include patients with either previous renal, hepatic, heart, lung, or other solid organ transplantation or hematopoietic cell transplant and experiencing subsequent documented locally advanced or metastatic cutaneous malign... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: University of Cincinnati, Cincinnati, Ohio
Conditions: Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Melanoma
Register for Updates
Investigating Dupilumab's Effect in Asthma by Genotype
NCT03694158
Recruiting
The Goal of this study is to investigate if individuals ages 12 years and older, carrying the IL-4RαR576 gene variant, will have a greater response to therapy acting directly on the anti-IL-4R. This will be conducted by examining the effect of a 48 week therapy with dupilumab on the rate of asthma exacerbations.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/30/2025
Locations: MetroHealth System, Cleveland, Ohio
Conditions: Asthma
Register for Updates
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
NCT03228667
Recruiting
This Phase 2b, multicohort, open-label clinical trial (QUILT-3.055) evaluates combination immunotherapies in patients with various advanced solid tumors who have progressed following prior PD-1/PD-L1 checkpoint inhibitor therapy. The trial includes six cohorts: Cohorts 1-4: Patients who progressed after an initial response (PR or CR) to prior PD-1/PD-L1 therapy, receiving combination therapy with N-803 and a PD-1/PD-L1 checkpoint inhibitor. (Closed to enrollment) Cohort 5: Patients who progres... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Cleveland Clinic - Main Site, Cleveland, Ohio
Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Register for Updates